Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists
Markus Glatzer, Pawel Leskow, Francesca Caparrotti, et al.
Translational Lung Cancer Research (2021) Vol. 10, Iss. 4, pp. 1960-1968
Open Access | Times Cited: 20

Showing 20 citing articles:

Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer
Arnaud Scherpereel, É. Martin, L. Brouchet, et al.
Lung Cancer (2023) Vol. 177, pp. 21-28
Open Access | Times Cited: 13
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
L. Carter, Vedika Apte, Arushi Shukla, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 1, pp. 65-79
Open Access | Times Cited: 5
Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non–Small Cell Lung Cancer
Wan‐Ming Chen, Mingchih Chen, Jeng-Guan Hsu, et al.
Radiology (2022) Vol. 305, Iss. 1, pp. 219-227
Closed Access | Times Cited: 20
Incorporating Lymph Node Size at CT as an N1 Descriptor in Clinical N Staging for Lung Cancer
Yura Ahn, Sang Min Lee, Jooae Choe, et al.
Radiology (2025) Vol. 314, Iss. 1
Closed Access
Enhancing Patient Selection in Stage IIIA-IIIB NSCLC: Invasive Lymph Node Restaging after Neoadjuvant Therapy
Robert Kwiatkowski, Marcin Zieliński, Jarosław Paluch, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 422-422
Open Access | Times Cited: 2
Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study
Song Guan, Sun Jifeng, Yuan Wang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 7
Open Access | Times Cited: 2
EBUS-TBNA in mediastinal staging of non-small cell lung cancer: comparison with pathological staging
Sara Braga, Rita Costa, Adriana Magalhães, et al.
Jornal Brasileiro de Pneumologia (2024), pp. e20230353-e20230353
Open Access | Times Cited: 2
Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer
Toon Allaeys, Lawek Berzenji, Patrick Lauwers, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1656-1656
Open Access | Times Cited: 10
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients
Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, et al.
Diagnostics (2023) Vol. 13, Iss. 3, pp. 400-400
Open Access | Times Cited: 4
Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants
Fei Gao, Xiaoqing You, Liu Yang, et al.
International Reviews of Immunology (2024) Vol. 43, Iss. 5, pp. 280-308
Closed Access | Times Cited: 1
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition
Maja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.
Radiation Oncology (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations
Jeremy P. Harris, Dylann Fujimoto, Misako Nagasaka, et al.
Clinical Lung Cancer (2022) Vol. 23, Iss. 4, pp. 333-344
Open Access | Times Cited: 5
Development and validation of a nomogram for predicting overall survival in patients with stage III-N2 lung adenocarcinoma based on the SEER database
Shengchao Zhang, Xiangzhi Xiao, Xuan Qin, et al.
Translational Cancer Research (2023) Vol. 12, Iss. 10, pp. 2742-2753
Open Access | Times Cited: 2
The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
Dailong Li, Wanqiang Li, Yaqi Pang, et al.
Medicine (2022) Vol. 101, Iss. 28, pp. e29580-e29580
Open Access | Times Cited: 3
Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy
Chenghao Qu, Rongyang Li, Jingyi Han, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 23, pp. 7188-7188
Open Access | Times Cited: 3
Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis
Jiaran Li, Li Li, Jingjing Wang, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study)
Mathilde Jacob, P. Fournel, Claire Tissot, et al.
Lung Cancer (2024) Vol. 194, pp. 107868-107868
Open Access
Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era
Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, et al.
Cancer Treatment and Research Communications (2024) Vol. 42, pp. 100852-100852
Open Access
Surgical decision-making in advanced-stage non–small cell lung cancer is influenced by more than just guidelines
Terrance Peng, Albert J. Farias, Kimberly A. Shemanski, et al.
JTCVS Open (2022) Vol. 11, pp. 286-299
Open Access | Times Cited: 2
Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the ‘radio talk’ webinars
Paolo Borghetti, Andrea Emanuele Guerini, Claudia Sangalli, et al.
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 5, pp. 549-559
Closed Access | Times Cited: 1
Page 1

Scroll to top